Eli Lilly (LLY) Offering Possible 10.8% Return Over the Next 36 Calendar Days

Eli Lilly’s most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $220.00 short put and a strike $200.00 long put offers a potential 10.8% return on risk over the next 36 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $220.00 by expiration. The full premium credit of $1.95 would be kept by the premium seller. The risk of $18.05 would be incurred if the stock dropped below the $200.00 long put strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.

The RSI indicator is at 68.37 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Eli Lilly

Eli Lilly buys remaining shares of Protomer Technologies in glucose-responsive insulin play
Wed, 14 Jul 2021 11:00:09 +0000
Eli Lilly & Co. said Wednesday it is acquiring the shares of Protomer Technologies it does not already own, in a deal it says has a potential value of more than $1 billion based on future development and commercial milestones. Lilly had previously purchased a 14% stake in the company, which has a proprietary peptide- and protein-engineering platform that can be used to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity. Protomer was founde

Lilly Announces Acquisition of Protomer Technologies
Wed, 14 Jul 2021 10:45:00 +0000
Eli Lilly and Company (NYSE: LLY) today announced the acquisition of Protomer Technologies (“Protomer”), a private biotech company. Protomer’s proprietary peptide- and protein-engineering platform is used to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity.

Biogen Partner Pushing On With Alzheimer’s Drug Despite Fracas
Tue, 13 Jul 2021 01:29:22 +0000
(Bloomberg) — Fresh off the historic but controversial approval of its Alzheimer’s drug Aduhelm with Biogen Inc. in the U.S., Japanese pharmaceutical company Eisai Co. says it’s pushing ahead with its second therapy to combat the disease, which has shown fewer side effects and could come in a more convenient form for patients.The Tokyo-based company’s plans for the second drug come amid renewed scrutiny around the U.S. Food and Drug Administration’s June approval of Aduhelm, which caused resign

Eli Lilly’s Mirikizumab Shows Mucosal Healing In Ulcerative Colitis Maintained For Up To One Year
Fri, 09 Jul 2021 14:45:34 +0000
Eli Lilly And Co (NYSE: LLY) has announced new Phase 2 data showing that gene expression changes induced by mirikizumab in patients with ulcerative colitis (UC) over a 12-week induction treatment were maintained for up to one year. In a previously published Phase 2 study, mirikizumab down-regulated several gene transcripts associated with inflamed mucosa and up-regulated gene transcripts correlated with healthy mucosa and markers of functional healing after 12 weeks. In this analysis, a set of d

Pharma Stock Roundup: GSK’s New Deal With Alector, MRK & AZN’s FDA Updates
Fri, 09 Jul 2021 12:10:12 +0000
Glaxo (GSK) to co-develop Alector’s two candidates for neurodegenerative diseases. FDA updates for Merck (MRK) and AstraZeneca (AZN)

Be Sociable, Share!

Related Posts